Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) EBITDA Margin (2022 - 2025)

Stoke Therapeutics has reported EBITDA Margin over the past 4 years, most recently at 4125.32% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 407757.0% year-over-year to 4125.32%; the TTM value through Dec 2025 reached 3.36%, up 24041.0%, while the annual FY2025 figure was 3.36%, 24041.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 4125.32% at Stoke Therapeutics, down from 357.38% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 71.22% in Q1 2025 and troughed at 4125.32% in Q4 2025.
  • A 4-year average of 810.6% and a median of 679.94% in 2023 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: soared 90996bps in 2024 and later plummeted -407757bps in 2025.
  • Year by year, EBITDA Margin stood at 768.88% in 2022, then dropped by -25bps to 957.71% in 2023, then skyrocketed by 95bps to 47.75% in 2024, then tumbled by -8539bps to 4125.32% in 2025.
  • Business Quant data shows EBITDA Margin for STOK at 4125.32% in Q4 2025, 357.38% in Q3 2025, and 168.51% in Q2 2025.